Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development o

American LLC ("NYSE American") that the Company was not in compliance with the continued lis

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actini

Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the a

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ:

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with s

Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radio

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

Together the allowances deepen protection across two priority franchises and reinforce a patent esta

NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actiniu

BURLINGTON, Mass. & BELOIT, Wis.--(BUSINESS WIRE)--Partnership combines NorthStar's commercial-scale

– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, indepen

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, indepen

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiophar

New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad

Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overwei

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get

ATHENS, Greece & BELOIT, Wisc.--(BUSINESS WIRE)--BIOEMTECH, a developer of high-resolution PET and S

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic On

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"),

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Aadi Bioscience (NASDAQ: AADI - Get Free

ProMetic Life Sciences (OTCMKTS:PFSCF - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM -

Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advanci

 Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outc

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"),

-  ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front l

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the dev

NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM), a leader in the

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on M

  During Friday's session, 445 companies made new 52-week lows.

Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesda

Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares climbed 62.3% to close at $5.00 o

Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares jumped 303.2% to $12.42. DPW Hold